Clinical Trial Update: Fursultiamine in Esophageal Squamous Cell Carcinoma Patients Who Receive Concurrent Chemoradiotherapy [Phase 2]

View source ↗

Summary

Phase 2 trial update on fursultiamine in esophageal squamous cell carcinoma patients undergoing concurrent chemoradiotherapy.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Squamous Cell Carcinoma

Drugs mentioned

• Fursultiamine (fursultiamine)

Snippet

Sponsor: National Cheng-Kung University Hospital | Conditions: Cancer Stem Cell | Phase 2 | Status: COMPLETED